Giuffrida, Domenica

Nuzzo, Anna Maria

Piccoli, Giorgina Barbara

Rolfo, Alessandro

Terzolo, Edoardo

Todros, Tullia

English

Nuzzo, ANNA MARIA

Institutional Research Information System University of Turin

 This is an author version of the contribution published on: Placenta, Volume 36, Issue 9, Page A38, 2015, © 2015 Published by Elsevier Inc., http://dx.doi.org/10.1016/j.placenta.2015.07.301  Indoleamine-2,3-deoxygenase (IDO1) oxygen-mediated regulation in normal, preeclamptic and chronic kidney disease (CKD) placentae  Edoardo Terzolo1, Giorgina Barbara Piccoli2, Anna Maria Nuzzo1, Domenica Giuffrida1, Tullia Todros1, Alessandro Rolfo1  1Dept. of Surgical Sciences, University of Turin, Turin, Italy; 2Dept. of Clinical and Biological Sciences, University of Turin, Turin, Italy  Background: IDO1 is key a heme-enzyme expressed by the human placenta. Through depletion of oxygen and tryptophan and kynuerenine production, it reduces proliferation and activity of T cells avoiding maternal-placental “rejection”. Moreover, IDO1 plays a role in reactive oxygen species management and it is inversely correlated to oxidative stress (OxS). Preeclampsia (PE) is a placenta-related syndrome characterized by abnormal maternal immune-response leading to aberrant placenta development and oxidative stress. According to the maternal/placental immune-maladaptation model, a role for IDO1 in PE pathogenesis has been hypothesized but never accurately demonstrated.  Herein, we characterized IDO1 placental oxygen-mediated regulation and its expression in PE and CKD placentae, clinically indistinguishable from PE despite a different etiology and no placental compromise. Methods: Human term placental villous explants (n = 21) were cultured for 12h at 20%pO2. Next, explants were treated oxygen-filled nanobubbles (OLNs-500 ul) and incubated in hypoxic conditions (3%pO2) or standard conditions (20%pO2) for 8 h. Untreated explants at 3%/20%pO2 were used as controls. Physiological (n = 15), PE (n = 15) and CKD (n = 21) placentae were collected. Placental biopsies and explants were processed for mRNA isolation. IDO1 mRNA levels were determined by Real Time PCR. Results: IDO1 mRNA levels were significantly increased in 20%pO2+OLNs (p<0.05, 8.3 Fold Increase; OxS condition) and 3%pO2 (p<0.05, 4.6 Fold Increase) explants vs 20%pO2 controls. Interestingly, 3%pO2+OLNs explants showed a reduction of IDO1 mRNA levels (p<0.05, 2.0 Fold decrease) vs 3%pO2 controls. IDO1 expression was significantly reduced in PE compared to both CKD and control placentae (p < 0.05). Conclusions: In the present study, we demonstrated, for the first time to our knowledge, IDO1 oxygen-mediated expression in the human placenta. IDO1 down-regulation further contributes to the pathological OxS environment typical of PE placentae. CKD placentae showed normal IDO1 expression, underlying a physiological placental environment. The definitive version is available at: http://www.placentajournal.org/article/S0143-4004(15)01270-9/fulltext  

INDOLEAMINE-2,3-DEOXYGENASE (IDO1) OXYGEN-MEDIATED REGULATION IN NORMAL, PREECLAMPTIC AND CHRONIC KIDNEY DISEASE (CKD) PLACENTAE

https://iris.unito.it/bitstream/2318/1561830/1/214510.pdf

INDOLEAMINE-2,3-DEOXYGENASE (IDO1) OXYGEN-MEDIATED REGULATION IN NORMAL, PREECLAMPTIC AND CHRONIC KIDNEY DISEASE (CKD) PLACENTAE

Abstract

Similar works

Full text

Available Versions

Institutional Research Information System University of Turin